Gemin X Biotechnologies Inc. To Present At The 25th Annual JPMorgan Healthcare Conference

MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies Inc. announced today that Dan Giampuzzi, the Company’s president and chief executive officer, will present an overview of Gemin X’s clinical trial progress with lead product candidate, GX15-070, at the 25th Annual JPMorgan Healthcare Conference on Tuesday, January 9, at 4:30 PM Pacific time at the Westin St. Francis Hotel in San Francisco. GX15-070 is currently being evaluated in Phase 2 trials as a 24-hour infusion every two weeks in the treatment of Hodgkin's lymphoma and myelofibrosis with myeloid metaplasia.